Evolva is collaborating on clinical trials using Veri-te™ resveratrol led by two speakers at this years’ conference in China, 18th – 20th October 2018. A third speaker is one of our Veri-te™ resveratrol customers.
Professor Peter Howe: Resveratrol benefits bone health in postmenopausal women – preliminary outcomes of the RESHAW trial
Prof. Peter Howe and Dr. R. Wong in U. Newcastle, Australia are currently leading a study with 160 postmenopausal women, for 24 months. 150 mg/day of Veri-te™ resveratrol. Focus on cardiometabolic, brain and bone health parameters. Completion of the study is expected by end of 2019. These interim results will be presented at the 5th International Conference on Resveratrol and Health. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370696
Nutrinovate won the 2018 Judges Award for Innovation at both the NutraAwards, Geneva and NutraAwards Asia for Reserol.
Dr. Scott Boyer: Assessment of Human Plasma Exposure to Resveratrol from a Buccal Adhesive Film Formulation
Dr. Boyer is speaking on behalf of Nutrinovate AB about the results of the clinical trials that were conducted on Reserol. The results of these trials showed the oral delivery system significantly enhances bioavailability of resveratrol.
Reserol is a dietary supplement designed to promote healthy ageing that features a novel oral delivery platform. The Reserol product range combines Veri-te™ resveratrol and Funtional Film Technology™ (FFT), Nutrinovate’s dissolvable oral film strip system that enables functional ingredients like resveratrol to be delivered to the body through the inside of the cheek. This technology has demonstrated a number of advantages like direct distribution to the bloodstream, faster bioavailability, and ease of use. Developed in Sweden, FFT is the result of 10 years of research and development, and is protected by a number of global patents.
Dr Karen Brown: Resveratrol and colorectal cancer – building the case for a prevention trial in high-risk patients
Prof. Karen Brown (U. of Leicester, UK) is leading a study with 10 subjects on a high fat diet for 2 weeks. Veri-te™ resveratrol (1g/d). Will study the interaction between resveratrol and a high fat diet in terms of changes in metabolic profiles, with a particular focus on fatty acids and ketones that may be involved in cancer development. Completion of the study is expected by mid-late 2019.